Long-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study

被引:38
|
作者
Atun, Rifat [1 ]
Chang, Angela Y. [1 ]
Ogbuoji, Osondu [1 ]
Silva, Sachin [1 ]
Resch, Stephen [1 ]
Hontelez, Jan [1 ]
Baernighausen, Till [1 ]
机构
[1] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA USA
来源
BMJ OPEN | 2016年 / 6卷 / 03期
关键词
PUBLIC HEALTH; CHILD-MORTALITY; HEALTH SYSTEMS; SOUTH-AFRICA; PREVENTION; PROGRAMS; COVERAGE; DISEASE; COST; RISK;
D O I
10.1136/bmjopen-2015-009656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To estimate the present value of current and future funding needed for HIV treatment and prevention in 9 sub-Saharan African (SSA) countries that account for 70% of HIV burden in Africa under different scenarios of intervention scale-up. To analyse the gaps between current expenditures and funding obligation, and discuss the policy implications of future financing needs. Design We used the Goals module from Spectrum, and applied the most up-to-date cost and coverage data to provide a range of estimates for future financing obligations. The four different scale-up scenarios vary by treatment initiation threshold and service coverage level. We compared the model projections to current domestic and international financial sources available in selected SSA countries. Results In the 9 SSA countries, the estimated resources required for HIV prevention and treatment in 2015-2050 range from US$98 billion to maintain current coverage levels for treatment and prevention with eligibility for treatment initiation at CD4 count of <500/mm(3) to US$261 billion if treatment were to be extended to all HIV-positive individuals and prevention scaled up. With the addition of new funding obligations for HIVwhich arise implicitly through commitment to achieve higher than current treatment coverage levelsoverall financial obligations (sum of debt levels and the present value of the stock of future HIV funding obligations) would rise substantially. Conclusions Investing upfront in scale-up of HIV services to achieve high coverage levels will reduce HIV incidence, prevention and future treatment expenditures by realising long-term preventive effects of ART to reduce HIV transmission. Future obligations are too substantial for most SSA countries to be met from domestic sources alone. New sources of funding, in addition to domestic sources, include innovative financing. Debt sustainability for sustained HIV response is an urgent imperative for affected countries and donors.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Comprehensive HIV/AIDS knowledge and HIV testing among men in sub-Saharan Africa: a multilevel modelling
    Tetteh, Justice Kanor
    Frimpong, James Boadu
    Budu, Eugene
    Adu, Collins
    Mohammed, Aliu
    Ahinkorah, Bright Opoku
    Seidu, Abdul-Aziz
    JOURNAL OF BIOSOCIAL SCIENCE, 2021, : 975 - 990
  • [42] Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs
    Doenhoff, M. J.
    Hagan, P.
    Cioli, D.
    Southgate, V.
    Pica-Mattoccia, L.
    Botros, S.
    Coles, G.
    Tchuente, L. A. Tchuem
    Mbaye, A.
    Engels, D.
    PARASITOLOGY, 2009, 136 (13) : 1825 - 1835
  • [43] Financing the HIV response in sub-Saharan Africa from domestic sources: Moving beyond a normative approach
    Remme, Michelle
    Siapka, Mariana
    Sterck, Olivier
    Ncube, Mthuli
    Watts, Charlotte
    Vassall, Anna
    SOCIAL SCIENCE & MEDICINE, 2016, 169 : 66 - 76
  • [44] HIV and viral hepatitis information needs among migrants from sub-Saharan Africa in Germany
    Koschollek, C.
    Kuehne, A.
    Thorlie, A.
    Tshibadi, C. Mputu
    Mayamba, P.
    Batemona, H.
    M'Bayo, R.
    Greiner, V. W.
    Dela Bursi, T.
    Bremer, V.
    Santos-Hoevener, C.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2017, 27
  • [45] Dynamics of non-cohabiting sex partnering in sub-Saharan Africa: a modelling study with implications for HIV transmission
    Omori, Ryosuke
    Chemaitelly, Hiam
    Abu-Raddad, Laith J.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 (06) : 451 - 457
  • [46] Implications of long-acting antiretrovirals (LAARVs) for HIV treatment in Sub-Saharan Africa
    Kokori, Emmanuel
    Olatunji, Gbolahan
    Ogieuhi, Ikponmwosa Jude
    Olusakin, Tobi Caleb
    Odufuwa, Oluwabusayo
    Aboje, John Ehi
    Igwe, Stephen Chukwuemeka
    Aderinto, Nicholas
    Olawade, David B.
    Adebayo, Yewande Abigail
    Oyewo, Oluwaseun
    Ezeano, Chimezirim
    DISCOVER PUBLIC HEALTH, 2024, 21 (01)
  • [47] Acceptability of HIV Self-Testing in Sub-Saharan Africa: Scoping Study
    Harichund, Charlene
    Moshabela, M.
    AIDS AND BEHAVIOR, 2018, 22 (02) : 560 - 568
  • [48] Acceptability of HIV Self-Testing in Sub-Saharan Africa: Scoping Study
    Charlene Harichund
    M. Moshabela
    AIDS and Behavior, 2018, 22 : 560 - 568
  • [49] Measuring patient engagement with HIV care in sub-Saharan Africa: a scoping study
    Keene, Claire M.
    Ragunathan, Ayesha
    Euvrard, Jonathan
    English, Mike
    McKnight, Jacob
    Orrell, Catherine
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (10)
  • [50] Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa
    Galadanci, Najibah A.
    Kanter, Julie
    LANCET HAEMATOLOGY, 2024, 11 (06): : e393 - e395